Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on May 25, 2018, 02:10:39 pm
-
A real-world analysis of AbbVie’s Mavyret (glecaprevir/pibrentasvir) found the hepatitis C virus (HCV) treatment was highly effective and well tolerated, MedPage Today reports.
Researchers conducted a retrospective longitudinal study of people with hep C starting Mavyret at 30 clinics in Italy. The study looked at the traditional indicator of whether someone has been cured of hep C, a sustained virologic response 12 weeks after completing therapy (SVR12), and also determined the proportion of those who had achieved an SVR four weeks after completing therapy (SVR4). Someone with an SVR4 stands an excellent chance of maintaining an undetectable hep C viral load for another eight weeks and then achieving an SVR12.
Read more...
https://www.hepmag.com/article/abbvies-mavyret-cures-hep-c-high-rates-realworld-analysis